Davis Todd C 4
4 · LIGAND PHARMACEUTICALS INC · Filed May 13, 2025
Insider Transaction Report
Form 4
Davis Todd C
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2025-05-09$104.57/sh+1,680$175,678→ 153,404 total - Purchase
Common Stock
2025-05-09$104.53/sh+2,307$241,150→ 155,711 total - Purchase
Common Stock
2025-05-09$105.67/sh+5,523$583,629→ 161,234 total
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.